ATE227563T1 - Stabile arzneistoffabgabekomplexe mit lipiden und verfahren zu deren herstellung - Google Patents

Stabile arzneistoffabgabekomplexe mit lipiden und verfahren zu deren herstellung

Info

Publication number
ATE227563T1
ATE227563T1 AT96902747T AT96902747T ATE227563T1 AT E227563 T1 ATE227563 T1 AT E227563T1 AT 96902747 T AT96902747 T AT 96902747T AT 96902747 T AT96902747 T AT 96902747T AT E227563 T1 ATE227563 T1 AT E227563T1
Authority
AT
Austria
Prior art keywords
drug delivery
production
complexes
lipids
stable drug
Prior art date
Application number
AT96902747T
Other languages
English (en)
Inventor
Xiang Gao
Leaf Huang
Original Assignee
Univ Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh filed Critical Univ Pittsburgh
Application granted granted Critical
Publication of ATE227563T1 publication Critical patent/ATE227563T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT96902747T 1995-01-23 1996-01-23 Stabile arzneistoffabgabekomplexe mit lipiden und verfahren zu deren herstellung ATE227563T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/376,701 US5795587A (en) 1995-01-23 1995-01-23 Stable lipid-comprising drug delivery complexes and methods for their production
PCT/US1996/000816 WO1996022765A1 (en) 1995-01-23 1996-01-23 Stable lipid-comprising drug delivery complexes and methods for their production

Publications (1)

Publication Number Publication Date
ATE227563T1 true ATE227563T1 (de) 2002-11-15

Family

ID=23486103

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96902747T ATE227563T1 (de) 1995-01-23 1996-01-23 Stabile arzneistoffabgabekomplexe mit lipiden und verfahren zu deren herstellung

Country Status (14)

Country Link
US (5) US5795587A (de)
EP (1) EP0814777B1 (de)
JP (1) JP4074338B2 (de)
CN (1) CN1177291A (de)
AT (1) ATE227563T1 (de)
AU (1) AU709773B2 (de)
CA (1) CA2211118C (de)
DE (1) DE69624801T2 (de)
DK (1) DK0814777T3 (de)
ES (1) ES2186769T3 (de)
IL (1) IL116856A0 (de)
PT (1) PT814777E (de)
WO (1) WO1996022765A1 (de)
ZA (1) ZA96503B (de)

Families Citing this family (432)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6989434B1 (en) * 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
FR2727679B1 (fr) * 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
US6383814B1 (en) 1994-12-09 2002-05-07 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US20030069173A1 (en) * 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6120794A (en) * 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
US6258792B1 (en) 1996-04-12 2001-07-10 University Of Pittsburgh Cationic cholesteryl derivatives containing cyclic polar groups
WO1997039019A1 (en) * 1996-04-12 1997-10-23 University Of Pittsburgh Novel cationic cholesteryl derivatives containing cyclic polar groups
CA2259179C (en) * 1996-07-03 2008-09-23 University Of Pittsburgh Emulsion formulations for hydrophilic active agents
US6251433B1 (en) 1996-08-13 2001-06-26 Chiron Corporation Polycationic polymers
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
ES2392246T3 (es) * 1996-11-12 2012-12-07 The Regents Of The University Of California Preparación de formulaciones estables de complejos de lípido-ácido nucleico para el suministro eficaz in vivo
US5962429A (en) * 1996-11-22 1999-10-05 University Of Iowa Complexes of adenovirus with cationic molecules
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US5948878A (en) * 1997-04-15 1999-09-07 Burgess; Stephen W. Cationic polymers for nucleic acid transfection and bioactive agent delivery
NZ333334A (en) * 1997-04-17 2001-06-29 Frank L Sorgi Delivery system for gene therapy to the brain
US6197332B1 (en) 1997-08-13 2001-03-06 Chiron Corporation Lipid-conjugated polyamide compounds and related compositions and methods thereof
US7157098B1 (en) * 1998-01-06 2007-01-02 Roman Perez-Soler Gene therapy of tumors using non-viral delivery system
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7244714B1 (en) * 1998-06-12 2007-07-17 Aradigm Corporation Methods of delivering aerosolized polynucleotides to the respiratory tract
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
NZ512244A (en) 1998-11-12 2003-12-19 Invitrogen Corp Polycationic transfection reagents for introducing anions into a cell
US6855549B1 (en) 1998-11-23 2005-02-15 The University Of Iowa Research Foundation Methods and compositions for increasing the infectivity of gene transfer vectors
ATE481487T1 (de) * 1998-11-27 2010-10-15 Ucb Sa Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US7083796B2 (en) 2000-06-20 2006-08-01 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
DE60021354T2 (de) * 1999-02-15 2006-04-27 Nippon Shinyaku Co., Ltd. Polynukleotide mit gekürzter kette und verfahren zu ihrer herstellung
EP1156812A4 (de) * 1999-02-23 2004-09-29 Isis Pharmaceuticals Inc Multipartikuläre formulierung
EP1156783B1 (de) * 1999-03-02 2007-10-24 Transave, Inc. Verkapselung biologisch aktiver komplexe in liposomen
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US20030104622A1 (en) * 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
EP1229931A4 (de) * 1999-10-07 2003-05-28 Corixa Corp Fusionsproteine aus mycobacterium tuberculosis
CA2395636A1 (en) * 1999-12-30 2001-07-12 Novartis Ag Novel colloid synthetic vectors for gene therapy
US6514523B1 (en) 2000-02-14 2003-02-04 Ottawa Heart Institute Research Corporation Carrier particles for drug delivery and process for preparation
IL151097A0 (en) 2000-02-23 2003-04-10 Smithkline Beecham Biolog Tumour-specific animal proteins
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
EP1383793B1 (de) 2000-03-29 2011-10-19 DGI BioTechnologies, L.L.C. Agonisten und antagonisten der rezeptoren des insulin und des igf-1
AR029540A1 (es) 2000-06-28 2003-07-02 Corixa Corp COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN
JP5610659B2 (ja) * 2000-07-21 2014-10-22 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 多成分生物学的輸送システム
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
JP4554883B2 (ja) * 2000-10-04 2010-09-29 協和発酵キリン株式会社 脂質膜による微粒子の被覆方法
DE10049010A1 (de) * 2000-10-04 2002-04-18 Boehringer Ingelheim Int Transferrin-Polykation/DNS-Komplexe für die systemische Therapie von Tumorerkrankungen mit zytotoxischen Proteinen
WO2002060412A2 (en) * 2001-02-01 2002-08-08 Board Of Regents Stabilised polymeric aerosols for pulmonary gene delivery
US20030096414A1 (en) * 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
JP2004535388A (ja) * 2001-04-30 2004-11-25 ターゲティッド ジェネティクス コーポレイション 脂質含有薬物送達複合体およびそれらの生成方法
JP2005504513A (ja) 2001-05-09 2005-02-17 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
AU2002309567A1 (en) * 2001-05-16 2002-12-03 The Children's Hospital Of Philadelphia Dna-antibody complexes to enhance gene transfer
AU2002348163A1 (en) * 2001-11-02 2003-05-19 Intradigm Corporation Therapeutic methods for nucleic acid delivery vehicles
DK2224012T3 (da) 2001-12-17 2013-05-13 Corixa Corp Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
US20060014695A1 (en) * 2002-02-01 2006-01-19 Hamidreza Ghandehari Hpma-polyamine conjugates and uses therefore
AU2003205380A1 (en) * 2002-02-01 2003-09-02 Intradigm Corporation Cationic polymers for use in therapeutic agent delivery
US7026465B2 (en) * 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
US7799523B2 (en) 2002-04-03 2010-09-21 Celltech R & D, Inc. Association of polymorphisms in the SOST gene region with bone mineral density
US20060193905A1 (en) * 2002-05-14 2006-08-31 University Of Louisville Research Foundation, Inc. Direct cellular energy delivery system
CN101863930A (zh) 2003-01-06 2010-10-20 科里克萨有限公司 一些氨烷基氨基葡糖苷磷酸酯化合物和它们的用途
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
DE10322123A1 (de) * 2003-05-12 2004-12-16 Novosom Ag Injizierbare Depots aus Liposomen und Polymeren zum Peptid- & Proteindelivery
HUE024996T2 (en) 2003-05-12 2016-01-28 Helion Biotech Aps Anti-MASP-2 antibodies
CA2529623A1 (en) 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
JP2007527431A (ja) * 2004-03-03 2007-09-27 ルバンス セラピュティックス 局所的診断及び治療用の輸送のための組成物及び方法
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
BRPI0508410B8 (pt) * 2004-03-03 2021-05-25 Revance Therapeutics Inc composições e métodos para a aplicação tópica e liberação transdérmica de toxinas botulínicas
EP2497831B1 (de) 2004-05-25 2014-07-16 Oregon Health and Science University TB-Impfung unter Verwendung von Impfvektoren auf HCMV-Basis
ES2631127T3 (es) 2004-06-10 2017-08-28 Omeros Corporation Métodos para tratar afecciones asociadas con la activación del complemento dependiente de MASP-2
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20060018896A1 (en) * 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
WO2005120495A1 (en) 2004-06-14 2005-12-22 Salama Zoser B Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody
ATE540970T1 (de) 2005-02-08 2012-01-15 Res Dev Foundation Zusammensetzungen in zusammenhang mit löslichen, g-proteingekoppelten rezeptoren (sgpcrs)
MX2007010674A (es) * 2005-03-03 2007-11-08 Revance Therapeutics Inc Composiciones y metodos para la aplicacion topica y el suministro transdermico de un oligopeptido.
ZA200707352B (en) 2005-03-03 2009-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
WO2006104890A2 (en) 2005-03-31 2006-10-05 Glaxosmithkline Biologicals Sa Vaccines against chlamydial infection
ITMI20050739A1 (it) * 2005-04-22 2006-10-23 Effebi Spa Piastrina di connsessione valvola-attuatore
DK2457926T3 (da) 2005-04-29 2015-01-05 Glaxosmithkline Biolog Sa Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
WO2007016597A2 (en) * 2005-07-29 2007-02-08 The Regents Of The University Of California Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
GB2430881B (en) * 2005-10-06 2010-10-13 Ntnu Technology Transfer As Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity
CN103126971A (zh) * 2005-11-17 2013-06-05 雷文斯治疗公司 减少非毒素蛋白质的肉毒杆菌毒素组合物和其局部施用及透皮递送方法
JP5460054B2 (ja) 2005-11-23 2014-04-02 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 腫瘍形成性ｒａｓ特異的細胞障害性化合物およびその使用法
EP2441846A3 (de) 2006-01-09 2012-07-25 The Regents Of the University of California Immunstimulierende Kombinationen aus TNFRSF, TLR, NLR, RHR, purinergischem Rezeptor, und Zytokin-Rezeptor-Antagonisten für Impfstoffe und die Tumorimmuntherapie
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US8084443B2 (en) 2007-10-01 2011-12-27 Longhorn Vaccines & Diagnostics Llc Biological specimen collection and transport system and methods of use
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
EP2423226A3 (de) 2006-11-10 2012-05-30 Amgen Inc. Diagnose und Therapie auf Basis von Antikörpern
EP2460828A3 (de) * 2006-11-10 2012-08-08 UCB Pharma, S.A. Antikörper und Diagnose
BRPI0720729A2 (pt) * 2006-12-29 2014-04-08 Revance Therapeutics Inc Moléculas de transporte que utilizam polipeptídeos hiv-tat de sequência inversa.
ES2714007T3 (es) 2007-04-09 2019-05-24 Univ Florida Composiciones de vectores rAAV que tienen proteínas de la cápside modificadas en tirosina y métodos para su uso
GB0707096D0 (en) * 2007-04-12 2007-05-23 Ntnu Technology Transfer As Method
DK2170384T3 (en) 2007-07-02 2016-07-25 Etubics Corp METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
EP2772267B1 (de) 2007-08-27 2016-04-27 Longhorn Vaccines and Diagnostics, LLC Immunogene Zusammensetzungen und Verfahren
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
UA97559C2 (uk) * 2007-11-08 2012-02-27 Оцука Фармасьютікал Ко., Лтд. Комплекс нуклеїнової кислоти і композиція для доставки нуклеїнової кислоти
CN101896201A (zh) * 2007-12-14 2010-11-24 安进公司 使用抗硬骨素抗体治疗骨折的方法
CA2724408A1 (en) * 2008-05-19 2009-11-26 The University Of North Carolina At Chapel Hill Methods and compositions comprising novel cationic lipids
GB0904941D0 (en) 2009-03-23 2009-05-06 Ntnu Technology Transfer As Composition
GB0904942D0 (en) 2009-03-23 2009-05-06 Ntnu Technology Transfer As Composition
WO2010120541A2 (en) 2009-03-31 2010-10-21 University Of Washington Compositions and methods for modulating the activity of complement regulatory proteins on target cells
WO2010135714A2 (en) 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Methods for modulating adipocyte expression using microrna compositions
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
US20120238509A1 (en) 2009-08-28 2012-09-20 Research Development Foundation Urocortin 2 analogs and uses thereof
DK2488203T3 (en) 2009-10-16 2017-03-13 Omeros Corp METHODS OF TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION
US20120288507A1 (en) 2009-12-18 2012-11-15 Amgen Inc. Wise binding agents and epitopes
BR112012018669A2 (pt) 2010-01-27 2017-09-05 Glaxosmithkline Biologicals Sa Proteína rv3616c modificada, uso de uma proteína rv3616c modificada, polinucleotídeo, uso de um polinucleotídeo, composição farmacêutica, composição imunogênica, proteína de fusão, e, polipeptídeo.
SG10201800541SA (en) 2010-04-23 2018-03-28 Univ Florida Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1)
EP2561073B1 (de) 2010-04-23 2016-08-24 University of Massachusetts Auf das zentralnervensystem abzielende vektoren und verfahren zu ihrer verwendung
EP3444346B1 (de) 2010-04-23 2022-07-27 University of Massachusetts Aav-basierte behandlung von cholesterinerkrankungen
EP2386647A1 (de) * 2010-05-10 2011-11-16 Qiagen GmbH Verfahren zur Transfektion einer eurkaryotischen Zelle
TR201802741T4 (tr) 2010-05-14 2018-03-21 Univ Oregon Health & Science Rekombinant hcmv ve rhcmv vektörleri ve bunların kullanımları.
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
NZ606591A (en) 2010-07-06 2015-02-27 Novartis Ag Cationic oil-in-water emulsions
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (de) 2010-10-01 2018-06-27 ModernaTX, Inc. Manipulierte nukleinsäuren und anwendungsverfahren dafür
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
EA201391248A1 (ru) 2011-03-01 2014-05-30 Эмджен Инк. Биспецифические связывающие агенты
AP3981A (en) 2011-03-25 2017-01-05 Amgen Inc Anti - sclerostin antibody crystals and formulations thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
BR112013025917A2 (pt) 2011-04-08 2016-12-20 Omeros Corp uso de um anticorpo masp-2 ou fragmento do mesmo que inibe ativação de complemento dependente de masp-2
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP3318635A1 (de) 2011-04-21 2018-05-09 University of Massachusetts Raav-basierte zusammensetzungen und verfahren zur behandlung von alpha-1-anti-trypsin-mangel
HUE049154T2 (hu) 2011-05-04 2020-09-28 Omeros Corp Készítmények a MASP-2-függõ komplement-aktiválás gátlására
CA2837651A1 (en) 2011-06-21 2012-12-27 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
JP6059220B2 (ja) 2011-07-06 2017-01-18 ノバルティス アーゲー 核酸を含む水中油型エマルジョン
MX350258B (es) 2011-07-06 2017-08-31 Novartis Ag Emulsiones cationicas de aceite en agua.
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
SI2739311T1 (en) 2011-08-04 2018-07-31 Amgen Inc. Method for the treatment of bone defect defects
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
US9849087B2 (en) 2011-11-08 2017-12-26 The Board Of Trustees Of The University Of Arkansas Methods and compositions for X-ray induced release from pH sensitive liposomes
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
EP3712168A3 (de) 2011-12-28 2020-10-14 Amgen Inc. Verfahren zur behandlung von alveolarknochenverlust durch verwendung von anti-sclerostin-antikörpern
EP3494989B1 (de) 2012-01-26 2025-07-16 Longhorn Vaccines and Diagnostics, LLC Zusammengesetzte antigensequenzen und impfstoffe
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
CN104411338A (zh) 2012-04-02 2015-03-11 现代治疗公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
MX357540B (es) 2012-04-06 2018-07-13 Omeros Corp Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de la hemoglobinuria paroxistica nocturna.
BR112014031522A2 (pt) 2012-06-18 2017-08-01 Omeros Corp métodos para inibir a ativação de complemento dependente de masp-3, para inibir a ativação de complemento dependente de masp-2 e para fabricar um medicamento
AU2013285488B2 (en) 2012-07-05 2018-03-22 Ucb Pharma S.A. Treatment for bone diseases
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
AU2013374345A1 (en) 2013-01-17 2015-08-06 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
AU2014212014A1 (en) 2013-02-01 2015-08-27 Amgen Inc. Administration of an anti-activin-A compound to a subject
EP2968391A1 (de) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Langlebige polynukleotidmoleküle
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
CN105188710A (zh) 2013-03-15 2015-12-23 葛兰素史密丝克莱恩生物有限公司 包含缓冲的氨基烷基氨基葡糖苷磷酸酯衍生物的组合物及其用于增强免疫应答的用途
CN115957297A (zh) * 2013-03-15 2023-04-14 节奏制药公司 药物组合物
JP6549554B2 (ja) 2013-03-15 2019-07-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア コレステロール流出を刺激する、減少した毒性を有するペプチド
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CA2917348A1 (en) 2013-07-11 2015-01-15 Moderna Therapeutics, Inc. Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
BR112016003361A2 (pt) 2013-08-21 2017-11-21 Curevac Ag vacina do vírus sincicial respiratório (rsv)
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
EP3041934A1 (de) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Chimäre polynukleotide
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (de) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynukleotide zur codierung von low-density-lipoprotein-rezeptor
JP2016539919A (ja) 2013-10-17 2016-12-22 オメロス コーポレーション Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
SI3071696T1 (sl) 2013-11-22 2019-11-29 Mina Therapeutics Ltd C/EBP alfa kratko delujoči RNA sestavki in postopki uporabe
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
CA2942515C (en) 2014-03-18 2025-12-09 University Of Massachusetts Raav-based compositions and methods for treating amyotrophic lateral sclerosis
PL4023249T3 (pl) 2014-04-23 2025-03-10 Modernatx, Inc. Szczepionki z kwasem nukleinowym
WO2015164786A1 (en) 2014-04-25 2015-10-29 University Of Massachusetts Recombinant aav vectors useful for reducing immunity against transgene products
HUE060907T2 (hu) 2014-06-25 2023-04-28 Acuitas Therapeutics Inc Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére
EP3169310A1 (de) 2014-07-15 2017-05-24 Life Technologies Corporation Zusammensetzungen mit lipidaggregaten und verfahren zur effizienten bereitstellung von molekülen an zellen
US20170204152A1 (en) 2014-07-16 2017-07-20 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3171895A1 (de) 2014-07-23 2017-05-31 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von intrabodys
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US10029012B2 (en) * 2014-09-05 2018-07-24 University Of Pittsuburgh—Of The Commonwealth System Of Higher Education Peptide-mediated intravesical delivery of therapeutic and diagnostic agents
EP3200830B1 (de) 2014-10-03 2020-09-09 University of Massachusetts Hocheffiziente bibliotheksidentifizierte aav-vektoren
WO2016061199A2 (en) 2014-10-14 2016-04-21 Research Development Foundation Methods for generating engineered enzymes
CN107073051B (zh) 2014-10-21 2021-08-24 马萨诸塞大学 重组aav变体及其用途
WO2016065349A2 (en) 2014-10-24 2016-04-28 University Of Maryland, Baltimore Short non-coding protein regulatory rnas (sprrnas) and methods of use
EP3212165B1 (de) 2014-10-30 2024-02-28 President and Fellows of Harvard College Freisetzung von negativ geladenen proteinen unter verwendung von kationischen lipiden
US9816080B2 (en) 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
WO2016100575A1 (en) 2014-12-16 2016-06-23 Board Of Regents Of The University Of Nebraska Gene therapy for juvenile batten disease
JP2018504380A (ja) 2014-12-18 2018-02-15 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｒｅｖｅｒｓｉｒ（商標）化合物
AU2016205208A1 (en) 2015-01-09 2017-07-06 Etubics Corporation Methods and compositions for ebola virus vaccination
EP3285788B1 (de) 2015-04-23 2024-12-18 University of Massachusetts Modulation der transgenexpression eines aav-vektors
EP3294448A4 (de) 2015-05-14 2018-12-12 Longhorn Vaccines and Diagnostics, LLC Schnellverfahren zur extraktion von nukleinsäuren aus biologischen proben
US20160346219A1 (en) 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods
PT3313829T (pt) 2015-06-29 2024-07-08 Acuitas Therapeutics Inc Formulações de lípidos e de nanopartículas lipídicas para a administração de ácidos nucleicos
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
JP6948313B6 (ja) 2015-09-17 2022-01-14 モデルナティエックス インコーポレイテッド 治療剤の細胞内送達のための化合物および組成物
EP3362102A1 (de) 2015-10-14 2018-08-22 Life Technologies Corporation Ribonukleoprotein-transfektionsmittel
EP4011451A1 (de) 2015-10-22 2022-06-15 ModernaTX, Inc. Impfstoffe gegen atemwegsvirus
EA201891000A1 (ru) 2015-10-22 2018-12-28 МОДЕРНАТиЭкс, ИНК. Вакцина против респираторно-синцитиального вируса
EP3365009A4 (de) 2015-10-22 2019-07-03 ModernaTX, Inc. Impfstoffe gegen herpes-simplex-virus
AU2016342045A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Human cytomegalovirus vaccine
WO2017070601A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (vzv)
IL310721B2 (en) 2015-10-23 2025-11-01 Harvard College Nucleobase editors and uses thereof
AU2016354117B2 (en) 2015-11-09 2019-11-28 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CA3007301A1 (en) 2015-12-04 2017-06-08 Board Of Regents, The University Of Texas System Slc45a2 peptides for immunotherapy
PL3386484T3 (pl) 2015-12-10 2022-07-25 Modernatx, Inc. Kompozycje i sposoby dostarczania środków terapeutycznych
LT3394030T (lt) 2015-12-22 2022-04-11 Modernatx, Inc. Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu
PL3394093T3 (pl) 2015-12-23 2022-05-16 Modernatx, Inc. Metody stosowania polinukleotydów kodujących ligand ox40
KR102528260B1 (ko) 2016-01-05 2023-05-04 유니버시티 오브 레스터 필요로 하는 대상체에서 섬유증의 억제 방법
MA43587A (fr) 2016-01-10 2018-11-14 Modernatx Inc Arnm thérapeutiques codant pour des anticorps anti-ctla-4
CA3011939A1 (en) 2016-02-02 2017-08-10 University Of Massachusetts Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
CA3012344A1 (en) 2016-02-12 2017-08-17 University Of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
CN115896106A (zh) 2016-03-01 2023-04-04 佛罗里达大学研究基金会有限公司 用于治疗显性视网膜色素变性的aav载体
MX2018010633A (es) 2016-03-03 2019-06-13 Univ Massachusetts Acido desoxirribonucleico (adn) lineal duplex de extremos cerrados para transferencia genica no viral.
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
MX2018011648A (es) 2016-03-31 2019-01-30 Omeros Corp Metodos para la inhibicion de fibrosis en un sujeto en necesidad del mismo.
CN109640959B (zh) 2016-04-29 2023-03-17 西奈山伊坎医学院 靶向先天免疫系统以诱导长期耐受性及解决动脉粥样硬化中的巨噬细胞累积
CN109475640B (zh) 2016-06-09 2023-03-10 库瑞瓦格欧洲公司 核酸被运载物的混合载运体
WO2017212007A1 (en) * 2016-06-09 2017-12-14 Curevac Ag Cationic carriers for nucleic acid delivery
JOP20170154B1 (ar) 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
CN110214183A (zh) 2016-08-03 2019-09-06 哈佛大学的校长及成员们 腺苷核碱基编辑器及其用途
WO2018031683A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
EP3510161A4 (de) 2016-08-23 2020-04-22 Akouos, Inc. Zusammensetzungen und verfahren zur behandlung von nicht altersbedingten hörschäden bei einer person
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US10457940B2 (en) 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
AU2017341849B2 (en) 2016-10-13 2024-03-21 University Of Massachusetts AAV capsid designs
KR102622411B1 (ko) 2016-10-14 2024-01-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
CA3043033A1 (en) 2016-11-10 2018-05-17 Translate Bio, Inc. Improved ice-based lipid nanoparticle formulation for delivery of mrna
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
EP3592853A1 (de) 2017-03-09 2020-01-15 President and Fellows of Harvard College Unterdrückung von schmerzen durch geneditierung
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
WO2018170322A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Crystal forms of amino lipids
CA3055653A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
EP4186888B1 (de) 2017-03-15 2025-11-26 ModernaTX, Inc. Verbindung und zusammensetzungen zur intrazellulären verabreichung von therapeutischen wirkstoffen
KR20240116572A (ko) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
CN110709095B (zh) 2017-04-05 2024-05-03 马萨诸塞大学 小基因治疗
CN110799492B (zh) 2017-04-28 2023-06-27 爱康泰生治疗公司 用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11485972B2 (en) 2017-05-18 2022-11-01 Modernatx, Inc. Modified messenger RNA comprising functional RNA elements
JP7285220B2 (ja) 2017-05-18 2023-06-01 モデルナティエックス インコーポレイテッド 連結したインターロイキン－１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子
WO2018232120A1 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
EP3638292A1 (de) 2017-06-14 2020-04-22 ModernaTX, Inc. Für koagulationsfaktor viii kodierende polynukleotide
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
US20200138921A1 (en) 2017-06-23 2020-05-07 The Trustees Of Columbia University In The City Of New York Methods of preventing and treating diseases characterized by synaptic dysfunction and neurodegeneration including alzheimer's disease
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
TWI881481B (zh) 2017-08-15 2025-04-21 美商歐米諾斯公司 用於治療和／或預防與造血幹細胞移植有關的移植物抗宿主病和／或瀰漫性肺泡出血和／或靜脈閉塞性病的方法
EP3676376B1 (de) 2017-08-30 2025-01-15 President and Fellows of Harvard College Hocheffiziente baseneditoren mit gam
EP3675817A1 (de) 2017-08-31 2020-07-08 Modernatx, Inc. Verfahren zur herstellung von lipidnanopartikeln
WO2019048632A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited STABILIZED COMPOSITIONS OF SMALL ACTIVATORY RNA (PARNA) OF HNF4A AND METHODS OF USE
US20200208152A1 (en) 2017-09-08 2020-07-02 Mina Therapeutics Limited Stabilized sarna compositions and methods of use
JP2021500878A (ja) 2017-10-12 2021-01-14 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 免疫療法のためのｔ細胞受容体
US12441998B2 (en) 2017-10-12 2025-10-14 The Trustees Of Columbia University In The City Of New York SLC2A1 lncRNA as a biologic and related treatments and methods
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
ES3062820T3 (en) 2017-11-08 2026-04-14 L E A F Holdings Group Llc Platinum complexes and uses thereof
WO2019094702A1 (en) 2017-11-10 2019-05-16 Cocoon Biotech Inc. Ocular applications of silk-based products
EP3714045A1 (de) 2017-11-22 2020-09-30 Modernatx, Inc. Für propionyl-coa-carboxylase-alpha- und beta-untereinheiten codierende polynukleotide zur behandlung von propionazidämie
CA3079428A1 (en) 2017-11-22 2019-05-31 Modernatx, Inc. Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
US11939601B2 (en) 2017-11-22 2024-03-26 Modernatx, Inc. Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
MA51523A (fr) 2018-01-05 2020-11-11 Modernatx Inc Polynucléotides codant pour des anticorps anti-virus du chikungunya
WO2019157145A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Gamma polyglutamated pemetrexed and uses thereof
WO2019157129A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
JP7491572B2 (ja) 2018-02-07 2024-05-28 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化ペメトレキセドおよびその使用
EP3749318A4 (de) 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC Gamma-polyglutamiertes raltitrexed und dessen verwendungen
US12310966B2 (en) 2018-02-07 2025-05-27 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
CA3090389A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated raltitrexed and uses thereof
EP3749314A4 (de) 2018-02-07 2022-02-23 L.E.A.F Holdings Group LLC Alpha-polyglutamatiertes methotrexat und dessen verwendungen
CA3090753A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated pralatrexate and uses thereof
WO2019160734A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
US12350271B2 (en) 2018-02-14 2025-07-08 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
JP7462950B2 (ja) 2018-02-14 2024-04-08 エル．イー．エー．エフ． ホールディングス グループ エルエルシー ガンマポリグルタミン酸化メトトレキセートおよびその使用
EP4169576A1 (de) 2018-03-23 2023-04-26 University of Massachusetts Gentherapeutika zur behandlung von knochenerkrankungen
EP3774879B1 (de) 2018-03-30 2026-01-28 Amgen Inc. C-terminale antikörpervarianten
WO2019200016A1 (en) 2018-04-10 2019-10-17 President And Fellows Of Harvard College Aav vectors encoding clarin-1 or gjb2 and uses thereof
EP3773745A1 (de) 2018-04-11 2021-02-17 ModernaTX, Inc. Messenger-rna mit funktionalen rna-elementen
EP3775211B1 (de) 2018-04-12 2023-04-05 MiNA Therapeutics Limited Sirt1-sarna kompositionen und methoden zu deren verwendung
JP7355394B2 (ja) 2018-05-03 2023-10-03 エル．イー．エー．エフ． ホールディングス グループ エルエルシー カロテノイド組成物およびその使用
CA3100050A1 (en) 2018-05-11 2019-11-14 Lupagen, Inc. Systems and methods for closed loop, real-time modifications of patient cells
KR20210045360A (ko) 2018-05-16 2021-04-26 신테고 코포레이션 가이드 rna 설계 및 사용을 위한 방법 및 시스템
US20210292400A1 (en) 2018-05-17 2021-09-23 Yiping W. Han Methods for treating, preventing and detecting the prognosis of colorectal cancer
WO2019226650A1 (en) 2018-05-23 2019-11-28 Modernatx, Inc. Delivery of dna
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
IL311042B1 (en) 2018-05-29 2026-04-01 Omeros Corp MASP-2 inhibitors and methods of use
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
WO2020014625A1 (en) 2018-07-13 2020-01-16 Akouos, Inc. Methods of treating non-syndromic sensorineural hearing loss
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
EP3833762A4 (de) 2018-08-09 2022-09-28 Verseau Therapeutics, Inc. Oligonukleotidzusammensetzungen zum targeting von ccr2 und csf1r und verwendungen davon
WO2020037102A1 (en) 2018-08-15 2020-02-20 University Of Florida Research Foundation, Inc. Methods of sensitizing tumors to treatment with immune checkpoint inhibitors
WO2020047201A1 (en) 2018-09-02 2020-03-05 Modernatx, Inc. Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency
US20220054610A1 (en) 2018-09-12 2022-02-24 University Of Florida Research Foundation, Inc. Slow-cycling cell-rna based nanoparticle vaccine to treat cancer
MX2021003015A (es) 2018-09-13 2021-07-15 Modernatx Inc Polinucleotidos que codifican glucosa-6-fosfatasa para el tratamiento de la glucogenosis.
WO2020056155A2 (en) 2018-09-13 2020-03-19 Modernatx, Inc. Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease
JP2022500444A (ja) 2018-09-14 2022-01-04 モダーナティエックス・インコーポレイテッドModernaTX, Inc. クリグラー−ナジャー症候群の治療のためのウリジン二リン酸グリコシルトランスフェラーゼ１ファミリー、ポリペプチドａ１をコードするポリヌクレオチド
CA3113025A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
WO2020061295A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. High-purity peg lipids and uses thereof
WO2020061367A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
IL281615B2 (en) 2018-09-21 2026-01-01 Acuitas Therapeutics Inc Systems and methods for producing lipid nanoparticles and liposomes
EP3856233A1 (de) 2018-09-27 2021-08-04 Modernatx, Inc. Arginase-1-codierende polynukleotide zur behandlung von arginasemangel
IL281470B2 (en) 2018-09-28 2025-08-01 Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
US12274733B2 (en) 2018-09-28 2025-04-15 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
EP3856260A1 (de) 2018-09-28 2021-08-04 President and Fellows of Harvard College Mutante reverse tetracyclin-transaktivatoren zur expression von genen
CA3116576A1 (en) 2018-10-18 2020-04-23 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
WO2020097409A2 (en) 2018-11-08 2020-05-14 Modernatx, Inc. Use of mrna encoding ox40l to treat cancer in human patients
EP3887522A1 (de) 2018-11-29 2021-10-06 University of Massachusetts Modulation von sptlc1 über rekombinante adeno-assoziierte vektoren
PT3908568T (pt) 2019-01-11 2024-09-30 Acuitas Therapeutics Inc Lípidos para a administração de agentes ativos por nanopartículas lipídicas
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
CN113874503A (zh) 2019-01-25 2021-12-31 辛瑟高公司 用于调节crispr活性的系统和方法
CA3131023A1 (en) 2019-02-22 2020-08-27 Michael R. Volkert Oxr1 gene therapy
JP7624728B2 (ja) 2019-02-25 2025-01-31 ユニバーシティ オブ マサチューセッツ Ｄｎａ結合ドメイントランスアクチベーター及びその使用
WO2020191233A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
EP3953473A1 (de) 2019-04-12 2022-02-16 MiNA Therapeutics Limited Sirt1-sarna-zusammensetzungen und verfahren zur verwendung
EP3952883A4 (de) 2019-04-12 2023-01-11 University of Massachusetts Gm3-synthasevektoren und deren verwendungen
EP3952988A4 (de) 2019-04-12 2023-06-28 University of Massachusetts Aav-cas13d-vektoren und verwendungen davon
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
CA3137135A1 (en) 2019-04-19 2020-10-22 University Of Massachusetts Gene therapies for stargardt disease (abca4)
EP3959232B1 (de) 2019-04-24 2024-10-16 University of Massachusetts Aav-capsid-chimäre antigenrezeptoren und verwendungen davon
EP3959324B1 (de) 2019-04-26 2025-09-17 President and Fellows of Harvard College Aav-vektoren zur codierung von mini-pcdh15 und verwendungen davon
EP3962521A1 (de) 2019-05-02 2022-03-09 University of Florida Research Foundation, Inc. Zusammensetzungen zur behandlung von diffusem intrinsischem ponsgliom
JP2022532078A (ja) 2019-05-08 2022-07-13 アストラゼネカ アクチボラグ 皮膚及び創傷のための組成物並びにその使用の方法
WO2020236815A1 (en) 2019-05-20 2020-11-26 University Of Massachusetts Minigene therapy
US20220387628A1 (en) 2019-06-24 2022-12-08 Modernatx, Inc. Messenger rna comprising functional rna elements and uses thereof
EP3987027A1 (de) 2019-06-24 2022-04-27 ModernaTX, Inc. Endonukleaseresistente messenger-rna und verwendungen davon
CA3127684A1 (en) 2019-07-19 2021-01-28 Synthego Corporation Stabilized crispr complexes
US20230000997A1 (en) 2019-08-06 2023-01-05 L.E.A.F. Holdings Group Llc Processes of preparing polyglutamated antifolates and uses of their compositions
CN114901253A (zh) 2019-08-14 2022-08-12 爱康泰生治疗公司 用于递送核酸的改进的脂质纳米颗粒
AU2020346062A1 (en) 2019-09-13 2022-03-24 Rutgers, The State University Of New Jersey AAV-compatible laminin-linker polymerization proteins
CA3155015A1 (en) 2019-09-19 2021-03-25 Modernatx, Inc. Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents
AU2020350759A1 (en) 2019-09-19 2022-03-31 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
IL293588B1 (en) 2019-12-04 2026-04-01 Omeros Corp 3-Amino-1-methylpyrazin-2(H1)-one derivatives as MASP-2 inhibitors, compositions containing them and uses thereof
BR112022010895A2 (pt) 2019-12-04 2022-09-06 Omeros Corp Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan
EP4069676A1 (de) 2019-12-04 2022-10-12 Omeros Corporation Masp-2-hemmer und verfahren zur verwendung
US12485166B2 (en) 2020-02-06 2025-12-02 Longhorn Vaccines And Diagnostics, Llc Vaccines for the treatment and prevention of zoonotic infections
KR20220157944A (ko) 2020-02-21 2022-11-29 아카우오스, 인크. 인간 대상체에서 비-연령-연관 청각 장애를 치료하기 위한 조성물 및 방법
US20230089312A1 (en) 2020-02-25 2023-03-23 University Of Massachusetts Inducible single aav system and uses thereof
TWI834025B (zh) 2020-03-06 2024-03-01 美商奥默羅斯公司 用於治療和/或預防冠狀病毒誘導的急性呼吸窘迫症候群的抑制masp-2的方法
US20230138409A1 (en) 2020-03-24 2023-05-04 Generation Bio Co. Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
JP2023520763A (ja) 2020-03-24 2023-05-19 ジェネレーション バイオ カンパニー ゴーシェ治療薬を発現するための非ウイルス性ｄｎａベクター及びその使用
WO2021202494A1 (en) 2020-03-31 2021-10-07 University Of Massachusetts Aav capsids variants and uses thereof
EP4126030A1 (de) 2020-04-01 2023-02-08 University Of Florida Research Foundation, Incorporated Multilamellarer rna-nanopartikelimpfstoff gegen sars-cov-2
AU2021265832A1 (en) 2020-04-29 2022-11-24 The Broad Institute, Inc. Machine learning accelerated protein engineering through fitness prediction
US20210346416A1 (en) * 2020-05-05 2021-11-11 Ralph Lipp Pharmaceutical Compositions and Methods for their Use in Antiviral Therapy
IL297761A (en) 2020-05-08 2022-12-01 Broad Inst Inc Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
AU2021275239A1 (en) 2020-05-21 2022-12-15 Board Of Regents, The University Of Texas System T cell receptors with VGLL1 specificity and uses thereof
EP4158005A1 (de) 2020-06-01 2023-04-05 ModernaTX, Inc. Phenylalaninhydroxylasevarianten und verwendungen davon
ES3054438T3 (en) 2020-07-16 2026-02-03 Acuitas Therapeutics Inc Cationic lipids for use in lipid nanoparticles
CN116406305A (zh) 2020-08-17 2023-07-07 麻省理工学院 Shank3基因治疗方法
US12129287B2 (en) 2020-09-14 2024-10-29 President And Fellows Of Harvard College Recombinant adeno associated virus encoding clarin-1 and uses thereof
EP4217376A4 (de) 2020-09-24 2024-10-09 University of Massachusetts Für nf1 codierende aav-vektoren und verwendungen davon
IE20210235A1 (en) 2020-10-20 2023-08-16 Longhorn Vaccines & Diagnostics Llc Immunogenic antigens
WO2022104131A1 (en) 2020-11-13 2022-05-19 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
KR20230117177A (ko) 2020-12-03 2023-08-07 유니버시티 오브 매사추세츠 진행성 골화성 섬유이형성증을 위한 신규 유전자 치료제의개발
EP4281559A4 (de) 2021-01-22 2024-12-04 University of Massachusetts Verwendung von neuen mirna-bindungsstellenkassetten zur detargetierung antigenpräsentierender zellen durch vektoren der raav-gentherapie
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
AU2022239614A1 (en) 2021-03-19 2023-10-12 Icahn School Of Medicine At Mount Sinai Compounds for regulating trained immunity, and their methods of use
US20240207374A1 (en) 2021-03-24 2024-06-27 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
WO2022204390A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
WO2022204370A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
US20240226025A1 (en) 2021-03-24 2024-07-11 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
US20240216288A1 (en) 2021-03-24 2024-07-04 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
TW202305133A (zh) 2021-03-26 2023-02-01 英商米納治療有限公司 Tmem173 sarna組合物及其使用方法
EP4313109A1 (de) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Apotransmission-polypeptide und deren verwendung bei der behandlung von krebs
WO2022232041A1 (en) 2021-04-26 2022-11-03 University Of Massachusetts Gene therapies for stargardt disease (abca4)
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
AU2022264509A1 (en) 2021-04-27 2023-12-14 Generation Bio Co. Non-viral dna vectors expressing therapeutic antibodies and uses thereof
US20240216535A1 (en) 2021-04-27 2024-07-04 Generation Bio Co. Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
US20240238418A1 (en) 2021-05-07 2024-07-18 University Of Florida Research Foundation, Inc. Car t cell therapy method
JP2024517903A (ja) 2021-05-10 2024-04-23 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム リミテッド 神経学的状態を治療するための薬学的組成物
EP4355882A2 (de) 2021-06-15 2024-04-24 Modernatx, Inc. Manipulierte polynukleotide zur zelltyp- oder mikroumgebungsspezifischen expression
WO2022271776A1 (en) 2021-06-22 2022-12-29 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
JP2024537775A (ja) 2021-09-30 2024-10-16 アコーオス インコーポレイテッド Ｋｃｎｑ４関連難聴を治療するための組成物及び方法
WO2023056044A1 (en) 2021-10-01 2023-04-06 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
TW202334080A (zh) 2021-11-08 2023-09-01 美商歐納醫療公司 用於遞送環狀聚核苷酸之脂質奈米粒子組合物
US20250011812A1 (en) 2021-11-23 2025-01-09 University Of Massachusetts Gene therapy for spinal muscular atrophy
EP4438615A4 (de) * 2021-11-25 2025-11-12 Univ Nagasaki Lipidverbindung, liposom, exosom, lipidnanopartikel und arzneimittelabgabesystem
WO2023099884A1 (en) 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use
CA3242402A1 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
CN114306641B (zh) * 2022-02-17 2024-12-03 大连民族大学 一种胆固醇氨基衍生物-蔗糖酯型阳离子脂质体/基因复合物及其制备方法
EP4482970A1 (de) 2022-02-23 2025-01-01 Massachusetts Institute of Technology Verfahren zur hochregulierung der expression von shank3
US20250327041A1 (en) 2022-02-24 2025-10-23 Io Biotech Aps Nucleotide delivery of cancer therapy
WO2023170435A1 (en) 2022-03-07 2023-09-14 Mina Therapeutics Limited Il10 sarna compositions and methods of use
CN119072330A (zh) 2022-03-14 2024-12-03 世代生物公司 异源初免加强疫苗组合物和使用方法
US20250221931A1 (en) 2022-03-25 2025-07-10 Modernatx, Inc. Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
WO2023196851A1 (en) 2022-04-06 2023-10-12 President And Fellows Of Harvard College Reversing aging of the central nervous system
WO2024026254A1 (en) 2022-07-26 2024-02-01 Modernatx, Inc. Engineered polynucleotides for temporal control of expression
US20260055426A1 (en) 2022-08-19 2026-02-26 Generation Bio Co. CLEAVABLE CLOSED-ENDED DNA (ceDNA) AND METHODS OF USE THEREOF
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024102677A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Circular rna compositions
WO2024102730A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and nanoparticle compositions for delivering polynucleotides
WO2024102762A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
WO2024105638A1 (en) 2022-11-18 2024-05-23 Jcr Pharmaceuticals Co., Ltd. Recombinant aav vectors and methods for treatment of hunter syndrome
WO2024125597A1 (en) 2022-12-14 2024-06-20 Providence Therapeutics Holdings Inc. Compositions and methods for infectious diseases
AU2023398825A1 (en) 2022-12-15 2025-06-26 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2024134199A1 (en) 2022-12-22 2024-06-27 Mina Therapeutics Limited Chemically modified sarna compositions and methods of use
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
US20240252520A1 (en) 2023-01-09 2024-08-01 Beth Israel Deaconess Medical Center, Inc. Therapeutic agents and their use for treating chronic wounds
WO2024151673A2 (en) 2023-01-09 2024-07-18 President And Fellows Of Harvard College Recombinant nucleic acid molecules and their use in wound healing
TW202449152A (zh) 2023-02-09 2024-12-16 美商艾拉倫製藥股份有限公司 Ｒｅｖｅｒｓｉｒ分子及其使用方法
CN116492977B (zh) * 2023-03-15 2025-01-28 中国农业大学 铁氢氧化物包裹的dna磷示踪剂及其制备方法与应用
WO2024197033A1 (en) 2023-03-21 2024-09-26 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of heart failure
WO2024196965A1 (en) 2023-03-23 2024-09-26 Carbon Biosciences, Inc. Parvovirus compositions and related methods for gene therapy
US12383615B2 (en) 2023-03-23 2025-08-12 Carbon Biosciences, Inc. Protoparvovirus compositions comprising a protoparvovirus variant VP1 capsid polypeptide and related methods
WO2024205657A2 (en) 2023-03-29 2024-10-03 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
EP4704816A1 (de) 2023-05-03 2026-03-11 ModernaTX, Inc. Polynukleotide zur codierung des transmembranleitungsregulators bei zystischer fibrose zur behandlung von zystischer fibrose
WO2024233422A1 (en) 2023-05-05 2024-11-14 Massachusetts Institute Of Technology Shank3 gene therapy approaches
EP4705481A2 (de) 2023-05-05 2026-03-11 Orna Therapeutics, Inc. Zirkuläre rna-zusammensetzungen und verfahren
WO2024241176A1 (en) 2023-05-24 2024-11-28 Jcr Pharmaceuticals Co., Ltd. Recombinant aav vectors and methods for treatment of diseases with central nervous system disorders
WO2025049690A1 (en) 2023-08-29 2025-03-06 Orna Therapeutics, Inc. Circular polyethylene glycol lipids
EP4520345A1 (de) 2023-09-06 2025-03-12 Myneo Nv Produkt
WO2025072482A1 (en) 2023-09-27 2025-04-03 Modernatx, Inc. Immunoglobulin a protease polypeptides, polynucleotides, and uses thereof
WO2025101501A1 (en) 2023-11-07 2025-05-15 Orna Therapeutics, Inc. Circular rna compositions
WO2025166238A1 (en) 2024-01-31 2025-08-07 Orna Therapeutics, Inc. Fast-shedding polyethylene glycol lipids
WO2025255199A1 (en) 2024-06-05 2025-12-11 Modernatx, Inc. Argininosuccinate synthase 1 and argininosuccinate lyase polypeptides and polynucleotides and uses thereof
WO2026006151A2 (en) 2024-06-24 2026-01-02 University Of Rochester Functionalization of ace-trna encoding synthetic linear picovectors
WO2026027887A2 (en) 2024-08-02 2026-02-05 Mina Therapeutics Limited Hbg1/2-sarna compositions and methods of use
WO2026072721A1 (en) 2024-09-25 2026-04-02 Carbon Biosciences, Inc. Parvovirus compositions and methods for gene therapy
WO2026085495A1 (en) 2024-10-18 2026-04-23 Generation Bio Co. Synthetic partially single-stranded nucleic acid compositions and uses and methods therefor

Family Cites Families (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4244946A (en) * 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4305872A (en) 1979-10-19 1981-12-15 Kenneth Wingrove Polypeptide derivatives
US4316891A (en) * 1980-06-14 1982-02-23 The Salk Institute For Biological Studies Extended N-terminal somatostatin
US5059591B1 (en) 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4946787A (en) * 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5550289A (en) * 1985-01-07 1996-08-27 Syntex (U.S.A.) Inc. N-(1,(1-1)-dialkyloxy)-and N-(1,(1-1)-dialkenyloxy alk-1-yl-N-N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5342921A (en) * 1985-03-28 1994-08-30 Chiron Corporation Superoxide dismutase fusion polypeptides for expression of mammalian proteins
US5374548A (en) * 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
US5540933A (en) * 1985-05-31 1996-07-30 La Jolla Cancer Research Foundation Isolation and use of fibronectin receptor
AU6408586A (en) 1985-10-03 1987-04-24 Biotechnology Research Partners Limited Novel lipoprotein-based drug-delivery systems
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US5560929A (en) 1986-08-18 1996-10-01 The Dow Chemical Company Structured copolymers and their use as absorbents, gels and carriers of metal ions
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5283634A (en) * 1987-06-18 1994-02-01 Canon Kabushiki Kaisha Luminance signal correcting method
US5008202A (en) * 1988-11-29 1991-04-16 Sequoia Turner Corporation Blood diluent for red blood cell analysis
US5196510A (en) * 1988-12-29 1993-03-23 Cytogen Corporation Molecular recognition units
US5043164A (en) * 1989-01-17 1991-08-27 The University Of Tennessee Research Corporation Blood-stable, cholesterol-free liposomes
DE3908047A1 (de) 1989-03-13 1990-09-20 Desitin Arzneimittel Gmbh Hochdisperse pharmazeutische zusammensetzung
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6214804B1 (en) * 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5165925A (en) 1989-05-02 1992-11-24 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Vaccine for immunizing fish against infectious pancreatic necrosis virus
US4958013A (en) * 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
US5286634A (en) 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
JPH05505102A (ja) 1989-12-21 1993-08-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 真核細胞の中に分子を配達する方法
US5705187A (en) * 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
US5583198A (en) * 1989-12-22 1996-12-10 Commonwealth Scientific And Industrial Research Organization Amino acids, peptides or derivatives thereof coupled to fats
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6147204A (en) 1990-06-11 2000-11-14 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
NZ239893A (en) * 1990-09-25 1993-11-25 Hoechst Japan A method for introducing a foreign dna into a cell
US5651964A (en) * 1990-12-04 1997-07-29 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by the adenoviral EIA gene
US5589392A (en) 1991-01-14 1996-12-31 Stratagene Nucleic acid construct encoding a nuclear transport peptide operatively linked to an inducible promoter
US5328984A (en) * 1991-03-04 1994-07-12 The United States As Represented By The Department Of Health & Human Services Recombinant chimeric proteins deliverable across cellular membranes into cytosol of target cells
WO1993003142A1 (en) * 1991-08-07 1993-02-18 Albert Einstein College Of Medicine Proliferation of hepatocyte precursors
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5298422A (en) * 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
DE4139001A1 (de) 1991-11-27 1993-06-03 Boehringer Mannheim Gmbh Verfahren zur einschleusung von nukleinsaeuren in zellen
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5756353A (en) * 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US5922859A (en) * 1992-02-01 1999-07-13 Boehringer Ingelheim International Gmbh Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells
CA2117378C (en) * 1992-02-24 2003-04-15 Steven K. H. Foung Htlv-i/htlv-ii assay and method
IL101241A (en) 1992-03-16 1997-11-20 Yissum Res Dev Co Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier
CA2131620A1 (en) 1992-03-20 1993-09-30 Louis C. Smith A dna transporter system and method of use
US6033884A (en) * 1992-03-20 2000-03-07 Baylor College Of Medicine Nucleic acid transporter systems and methods of use
US6113946A (en) * 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
WO1993019768A1 (en) 1992-04-03 1993-10-14 The Regents Of The University Of California Self-assembling polynucleotide delivery system
EP0646178A1 (de) 1992-06-04 1995-04-05 The Regents Of The University Of California Expression kassette mit im säugetier wirt funktionnellen regulator sequenzen
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5266106A (en) 1992-10-22 1993-11-30 Xerox Corporation Ink compositions with dendrimer grafts
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US5674977A (en) 1993-02-05 1997-10-07 The Ontario Cancer Institute Branched synthetic peptide conjugate
AU6133394A (en) 1993-02-09 1994-08-29 Scripps Research Institute, The Targeting and delivery of genes and antiviral agents into cells by the adenovirus penton
US5532142A (en) * 1993-02-12 1996-07-02 Board Of Regents, The University Of Texas System Method of isolation and purification of fusion polypeptides
WO1994018834A1 (en) * 1993-02-16 1994-09-01 Virginia Tech Intellectual Properties, Inc. Polyelectrolyte dna conjugation and genetic transformation of an animal
US5491074A (en) * 1993-04-01 1996-02-13 Affymax Technologies Nv Association peptides
DE4311651A1 (de) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
AU6568594A (en) 1993-04-14 1994-11-08 Boehringer Mannheim Gmbh Nucleic acid tranfer peptides and their use for injecting nucleic acids into eucaryotic cells
US5554382A (en) 1993-05-28 1996-09-10 Aphios Corporation Methods and apparatus for making liposomes
US5776486A (en) * 1993-05-28 1998-07-07 Aphios Corporation Methods and apparatus for making liposomes containing hydrophobic drugs
EP1624068A1 (de) * 1993-06-01 2006-02-08 Life Technologies Inc. Genetische Impfung mit kationischen Lipidstoffen
US5578475A (en) 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
JP3785187B2 (ja) 1993-07-14 2006-06-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 樹枝状体ポリ陽イオンを含む自己集合性ポリヌクレオチド配送系
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
WO1995013365A1 (en) * 1993-11-09 1995-05-18 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
AU682253B2 (en) * 1994-01-28 1997-09-25 Immunex Corporation CD 69 transcriptional regulatory elements
US5928944A (en) * 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
US6075012A (en) * 1994-02-11 2000-06-13 Life Technologies, Inc. Reagents for intracellular delivery of macromolecules
US6077835A (en) * 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
JP4285766B2 (ja) 1994-03-23 2009-06-24 オハイオ ユニバーシティ 緻密にした核酸および細胞へのデリバリ
US5844107A (en) * 1994-03-23 1998-12-01 Case Western Reserve University Compacted nucleic acids and their delivery to cells
US5972901A (en) 1994-03-23 1999-10-26 Case Western Reserve University Serpin enzyme complex receptor--mediated gene transfer
FR2719316B1 (fr) * 1994-04-28 1996-05-31 Idm Nouveaux complexes d'acide nucléique et de polymère, leur procédé de préparation et leur utilisation pour la transfection de cellules.
US5670347A (en) 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
US5908635A (en) * 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
AUPM747694A0 (en) * 1994-08-16 1994-09-08 Commonwealth Scientific And Industrial Research Organisation Delivery of nucleic acids and peptides
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5885613A (en) * 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5744355A (en) * 1994-10-18 1998-04-28 Mayo Foundation For Medical Education And Research cDNA cloning and expression of human liver estrogen sulfotransferase
US5627159A (en) * 1994-10-27 1997-05-06 Life Technologies, Inc. Enhancement of lipid cationic transfections in the presence of serum
US5587441A (en) 1994-11-08 1996-12-24 Cornell Research Foundation, Inc. Hyperbranched polymers from AB monomers
US5840710A (en) * 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US5939401A (en) * 1994-12-09 1999-08-17 Genzyme Corporation Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
US5948767A (en) 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US5719131A (en) * 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5650096A (en) * 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5635487A (en) * 1994-12-29 1997-06-03 Wolff; Jon A. Amphipathic, micellar delivery systems for biologically active polyions
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US5753262A (en) * 1995-06-07 1998-05-19 Aronex Pharmaceuticals, Inc. Cationic lipid acid salt of 3beta N- (N', N'-dimethylaminoethane) - carbamoyl!cholestrol and halogenated solvent-free preliposomal lyophilate thereof
US5705385A (en) * 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US20030069173A1 (en) * 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
US5976567A (en) 1995-06-07 1999-11-02 Inex Pharmaceuticals Corp. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
EP0874910A4 (de) * 1995-06-07 1999-04-21 Life Technologies Inc Durch peptide erhöhte kationische lipid transfektionen
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US7422902B1 (en) * 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5908777A (en) 1995-06-23 1999-06-01 University Of Pittsburgh Lipidic vector for nucleic acid delivery
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6033848A (en) * 1995-08-01 2000-03-07 Incyte Pharmaceuticals, Inc. Human ice homolog
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US6086913A (en) * 1995-11-01 2000-07-11 University Of British Columbia Liposomal delivery of AAV vectors
US6126964A (en) 1996-01-04 2000-10-03 Mirus Corporation Process of making a compound by forming a polymer from a template drug
AUPN741696A0 (en) 1996-01-05 1996-01-25 Commonwealth Scientific And Industrial Research Organisation Delivery of nucleic acids ii
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US5811297A (en) 1996-03-07 1998-09-22 Amba Biosciences, Llc Immortalized hematopoietic cell lines, cell system thereof with stromal cells, in vitro, ex vivo and in vivo uses, & in vitro generation of dendritic cells and macrophages
JPH09268195A (ja) * 1996-04-02 1997-10-14 Mitsubishi Chem Corp 蔗糖脂肪酸エステルの製造方法
DK0941066T3 (da) * 1996-08-26 2004-02-23 Transgene Sa Kationisk lipid-nukleinsyre-komplekser
US5905777A (en) * 1996-09-27 1999-05-18 At&T Corp. E-mail paging system
US5861397A (en) * 1996-10-03 1999-01-19 Vical Incorporated Piperazine based cytofectins
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6224903B1 (en) * 1996-10-11 2001-05-01 Sequus Pharmaceuticals, Inc. Polymer-lipid conjugate for fusion of target membranes
ES2392246T3 (es) * 1996-11-12 2012-12-07 The Regents Of The University Of California Preparación de formulaciones estables de complejos de lípido-ácido nucleico para el suministro eficaz in vivo
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
US5948925A (en) 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US6835395B1 (en) 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
DE69941447D1 (de) * 1998-01-05 2009-11-05 Univ Washington Erhöhter transport unter benutzung membranzerstörender stoffe
US6271209B1 (en) * 1998-04-03 2001-08-07 Valentis, Inc. Cationic lipid formulation delivering nucleic acid to peritoneal tumors
US6043390A (en) * 1998-04-03 2000-03-28 The Regents Of The University Of California Pentaerythritol lipid derivatives and nucleic-acid complexes
US6011202A (en) * 1998-07-28 2000-01-04 Delta And Pine Land Company Soybean cultivar 95-00981
NZ512244A (en) * 1998-11-12 2003-12-19 Invitrogen Corp Polycationic transfection reagents for introducing anions into a cell
US6773920B1 (en) * 1999-03-31 2004-08-10 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
US6037176A (en) * 1999-06-25 2000-03-14 Isis Pharmaceuticals Inc. Antisense inhibition of integrin beta 3 expression
EP1337664A4 (de) * 2000-10-27 2005-01-19 Invitrogen Corp Verfahren zur einführung von antisense-oligonukleotiden in eukaryontische zellen
US20040102606A1 (en) * 2001-04-24 2004-05-27 Danuta Balicki Histone H2A -derived peptides useful in gene delivery
JP2004535388A (ja) * 2001-04-30 2004-11-25 ターゲティッド ジェネティクス コーポレイション 脂質含有薬物送達複合体およびそれらの生成方法
CA2513072A1 (en) 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes

Also Published As

Publication number Publication date
JP4074338B2 (ja) 2008-04-09
US7993672B2 (en) 2011-08-09
MX9705572A (es) 1998-06-28
US20100184953A1 (en) 2010-07-22
DE69624801D1 (de) 2002-12-19
JPH10512882A (ja) 1998-12-08
US7655468B2 (en) 2010-02-02
EP0814777B1 (de) 2002-11-13
WO1996022765A1 (en) 1996-08-01
AU4703796A (en) 1996-08-14
CA2211118A1 (en) 1996-08-01
US20120178702A1 (en) 2012-07-12
EP0814777A1 (de) 1998-01-07
PT814777E (pt) 2003-03-31
DE69624801T2 (de) 2003-04-10
AU709773B2 (en) 1999-09-09
ES2186769T3 (es) 2003-05-16
IL116856A0 (en) 1996-07-23
DK0814777T3 (da) 2003-03-03
US5795587A (en) 1998-08-18
US20080153166A1 (en) 2008-06-26
US20130281382A1 (en) 2013-10-24
US8771728B2 (en) 2014-07-08
ZA96503B (en) 1996-08-07
CA2211118C (en) 2009-06-30
CN1177291A (zh) 1998-03-25

Similar Documents

Publication Publication Date Title
ATE227563T1 (de) Stabile arzneistoffabgabekomplexe mit lipiden und verfahren zu deren herstellung
AU7576896A (en) Lipopolyamines as transfection agents and their pharmaceutical applications
ATE41307T1 (de) Waessrige, eine fettloesliche wirksubstanz enthaltende loesung sowie verfahren zu deren herstellung.
DE69433723D1 (de) Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
NO905264L (no) Fremgangsmaate for fremstilling av biologisk aktivt protein
NO20002788D0 (no) Nye forbindelser
BG91270A (bg) Антивирусно и антибактериално средство и метод за използването му
DE59303365D1 (de) Derivate in der vitamin d-reihe mit modifikationen in der 20 position, verfahren zu ihrer herstellung, zwischenprodukte für dieses verfahren, diese derivate enthaltende pharmazeutische präparate sowie deren verwendung zur herstellung von arzneimitteln
MEP10408A (en) Platinum derivative pharmaceutical formulations
EP0657534A4 (de) Antiallergisches agen.
ES2147320T3 (es) Derivados de n-(3-benzofuranil)urea.
ES2195040T3 (es) Conjugado que incluye un principio activo, un polipeptido y varios polieteres y su uso como medicamento.
HUT58037A (en) Process for producing n-2,3-butadienyl tri- and tetraaminoalkane derivatives
ATE226065T1 (de) Feste instant-release-darreichungsformen und verfahren zu ihrer herstellung
AR002272A1 (es) Uso de amidas de fenilciclohexilcarboxilicos
ATE25708T1 (de) Biologisch aktive konjugate, ihre herstellung und ihre anwendung.
DE68906572D1 (de) Peptide mit inhibitorischer wirkung auf enzymatische systeme, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ES2031959T3 (es) Procedimiento para preparar acidos 3,5-dihidroxicarboxilicos y sus derivados.
DE3576155D1 (de) Diazohydroxypyrazinverbindungen, verfahren zu deren herstellung und verwendung.
DE3585936D1 (de) Biologisch aktive peptide, deren verfahren zur herstellung und pharmazeutische zusammensetzungen.
DE59004814D1 (de) t-PA-Solubilisierung.
EP0139767A4 (de) Organophosphoresterabkömmlinge, deren herstellung und schädlingsvernichter, die diese als aktive bestandteile aufweisen.
DE68909451D1 (de) Peptide mit inhibitorischer wirkung auf enzymatische systeme, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
AR003920A1 (es) Metodo para producir complejos droga/lipidos que tienen cargas positivas en exceso con respecto a la droga y los complejos droga/lipidos obtenidos condicho metodo y metodo para dispensar una droga a una persona.
ATE75485T1 (de) Biologisch aktive peptide, deren verfahren zur herstellung und pharmazeutische zusammensetzungen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0814777

Country of ref document: EP

REN Ceased due to non-payment of the annual fee